The FDA has restarted the public release of complete response letters (CRLs), citing a renewed “commitment to transparency,” according to BioCentury. A new batch of rejection letters includes a camrelizumab plus rivoceranib combination from Hengrui and Elevar Therapeutics. The resumption follows reporting that the agency had paused CRL releases amid legal and policy considerations, highlighting continued tension between disclosure and sensitive content. For biopharma, each CRL restart raises near-term visibility on where development programs are stumbling—especially in oncology and combination regimens. Companies receiving CRLs typically face renewed timelines and remediation plans tied to the specific deficiencies noted in each letter.